Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim joins Structural Genomics Consortium

Boehringer Ingelheim joins Structural Genomics Consortium

7th May 2013

Boehringer Ingelheim is to work alongside the Structural Genomics Consortium (SGC) in order to further its efforts to develop novel therapies for previously uncurable diseases.

The firm has become a member of the international consortium, which is based at the Universities of Toronto and Oxford and aims to promote research into protein structures and epigenetics.

Boehringer Ingelheim will work with the SGC on different research projects to identify small molecules that can enhance or inhibit the activity of proteins involved in epigenetic control, potentially creating new treatment approaches for conditions such as cancer, diabetes, inflammation, obesity and several psychiatric diseases.

Dr Adrian Carter, corporate vice-president of global research networking at Boehringer Ingelheim, said: "This is a unique opportunity to work on unprecedented science in a precompetitive public-private partnership with a large global scientific network."

Last month, the firm made an investment in the ocular health-focused company Eyevensys through its Boehringer Ingelheim Venture Fund, with the aim of supporting its innovative drug research.ADNFCR-8000103-ID-801581629-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.